相关实验视频

Updated: Jan 13, 2026

Assessing the Autonomic and Behavioral Effects of Passive Motion in Rats using Elevator Vertical Motion and Ferris-Wheel Rotation

Assessing the Autonomic and Behavioral Effects of Passive Motion in Rats using Elevator Vertical Motion and Ferris-Wheel Rotation

Published on: February 7, 2020

乙醇胺通过抑制内耳二氧化碳水酶2和减少内淋巴体积来缓解运动恶心

Miao-Miao Chen¹, Chao-Yue Tian¹, Jian-Gang Ge²

¹Institute of Special Environmental Medicine, Medical School, and Co-innovation Center of Neuroregeneration, Nantong University, 9 Seyuan Road, Chongchuan District, Nantong, Jiangsu Province, 226019, China.

Neuropharmacology

|January 9, 2026

概括

运动性疾病可以通过向内耳碳酸无水酶2 (CA2) 来治疗. 用乙胺 (AZ) 抑制CA2可减少运动恶性症状和内耳液体积累,提供一种新的药物开发策略.

科学领域:

神经科学是一个神经科学.
耳鼻喉科耳鼻喉科耳鼻喉科
药理学药理学是指药理学的学科.

背景情况:

运动病影响航空航天,航空,海事和车辆旅行.
目前的治疗方法会引起中枢神经系统的副作用,需要新的药物点.
内耳功能障碍与运动恶性病的发生有关.

研究的目的:

为了研究碳酸二酶2 (CA2) 在运动恶心期间在内耳中的作用.
评估一种CA抑制剂阿西塔佐胺 (AZ) 的有效性,以预防运动恶心.
阐明AZ抗运动疾病效应的潜在机制.

主要方法:

在几内亚猪和小鼠中通过旋转刺激诱导运动恶心.
在内耳测量CA2表达.
作为预治疗,使用乙胺 (AZ) 进行治疗.
评估运动性 motion sickness 的行为症状.
量化内耳内淋巴体的体积. 内耳内淋巴体的体积.
分析前体细胞中的细胞内离子度和酶活性.

主要成果:

旋转刺激在内耳上调节了CA2表达.
乙胺 (AZ) 前期治疗缓解了运动恶心症状和减少了内淋巴体积.
AZ抑制了细胞内H+的增加,并调节了Na+/K+的平衡.
在前庭上皮质细胞中,AZ抑制了Na+-K+-ATPase活性.

结论:

内耳CA2参与引发运动恶心.
乙胺 (AZ) 通过准内耳机制,表现出抗运动疾病的作用.
CA2抑制为运动性疾病提供了一种新的治疗策略,并可能减少副作用.

关键词:

阿尔多氨酸是一种阿尔多氨酸.碳酸无水酶2 (CA2) 是一种内淋巴体积的内淋巴体积.内耳是指内耳的内部部分.运动病是运动病.旋转刺激的旋转刺激

更多相关视频

How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants

How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants

Published on: December 14, 2014

Long-term Sensory Conflict in Freely Behaving Mice

Long-term Sensory Conflict in Freely Behaving Mice

Published on: February 20, 2019

相关概念视频

Equilibrium and Balance

Equilibrium and Balance

The inner ear assumes dual functionalities of auditory perception and equilibrium maintenance. The vestibule is the organ responsible for balance. This organ contains mechanoreceptors, specifically hair cells, endowed with stereocilia, which aid in deciphering information regarding the position and motion of our heads. Two intrinsic components, the utricle and saccule, help perceive head position, while the semicircular canals track head movement. Neurological messages initiated in the...

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Pathophysiology of Vomiting

Pathophysiology of Vomiting

Vomiting is a complex physiological response to expel harmful or irritating substances from the body. It's a defensive mechanism triggered by stimuli like poisons, microbial toxins, cytotoxic drugs, and mechanical abdominal distension. The process is centrally coordinated by the vomiting (or emetic) center located in the medulla of the brainstem. This area, rich in muscarinic M1, histamine H1, neurokinin 1 (NK1), and serotonin 5-HT3 receptors, coordinates the act of vomiting through...

Cholinergic Antagonists: Therapeutic Uses

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...